albumin conjugate comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-12. Numbers and descriptions here follow the published literature rather than marketing material.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
intermediates in biosynthesis, in post-translational formation of proteins, in a physiological role (e.g. components of bacterial cell walls, neurotransmitters and toxins), natural or man-made pharmacological compounds, present in meteorites or used in prebiotic experiments (such as the Miller–Urey experiment), might be important neurotransmitters, such as γ-aminobutyric acid, and can play a crucial role in cellular bioenergetics, such as creatine.
Data from Erection and Maintenance Manual for P-51D and P-51K, P-51 Tactical Planning Characteristics & Performance Chart, The Great Book of Fighters, and Quest for PerformanceGeneral characteristics Crew: 1 Length: 32 ft 3 in (9.83 m) Wingspan: 37 ft 0 in (11.28 m) Height: 13 ft 4.5 in (4.077 m) tail wheel on ground, vertical propeller blade Wing area: 235 sq ft (21.8 m2) Aspect ratio: 5.83 Airfoil: NAA/NACA 45–100 Empty weight: 7,635 lb (3,463 kg) Gross weight: 9,200 lb (4,173 kg) Max takeoff weight: 12,100 lb (5,490 kg) Fuel capacity: 269 US gal (224 imp gal; 1,020 L) Zero-lift drag coefficient: 0.0163 Drag area: 3.80 sqft (0.35 m²) Powerplant: 1 × Packard (Rolls-Royce) V-1650-7 Merlin 12-cylinder liquid cooled engine, 1,490 hp (1,110 kW) at 3,000 rpm; 1,720 hp (1,280 kW) at WEP Propellers: 4-bladed Hamilton Standard constant-speed, variable-pitch, 11 ft 2 in (3.40 m) diameter Performance
Adsorption removes a soluble impurity from a feed stream by trapping it on the surface of a solid material, such as activated carbon, that forms strong non-covalent chemical bonds with the impurity. Chromatography employs continuous adsorption and desorption on a packed bed of a solid to purify multiple components of a single feed stream. In a laboratory setting, mixture of dissolved materials are typically fed using a solvent into a column packed with an appropriate adsorbent, and due to different affinities for solvent (moving phase) versus adsorbent (stationary phase) the components in the original mixture pass through the column in the moving phase at different rates, which thus allows to selectively collect desired materials out of the initial mixture. Smelting produces metals from raw ore, and involves adding chemicals to the ore and heating it up to the melting point of the metal. Refining is used primarily in the petroleum industry, whereby crude oil is heated and separated into stages according to the condensation points of the various elements. Distillation, widely used in petroleum refining and in purification of ethanol separates volatile liquids on the basis of their relative volatilities. There are several type of distillation: simple distillation, steam distillation etc. Water purification combines a number of methods to produce potable or drinking water.
The 1980s MGN W12 F1 engine used rotary valves but never raced. Between 2002 and 2004 the Australian developer Bishop Innovation and Mercedes-Ilmor tested rotary valves for a F1 V10 engine. Bishop Innovations' patent for the rotary valve engine was bought out by BRV Pty Ltd, owned by Tony Wallis, one of the valves original designers. BRV has constructed several functional motors using the rotary valve technology, such as a Honda CRF 450, which had greater torque at both low (17% increase) and high (9% increase) engine speeds, and also produced more brake horsepower up to around 30% more at functional engine speeds. The engine was also considerably smaller and lighter, as the cylinder head assembly was not as large. A company in the UK called Roton Engine Developments made some progress in 2005 with a two-rotor (one for inlet and one for exhaust) single-cylinder Husaberg motorcycle engine. They filed patents and got an example running in 2006, but were backed by MG Rover which subsequently went bust, leaving Roton without enough funds to continue. The designs surfaced some years later in Australia with Engine Developments Australia Pty Ltd. A prototype casting was produced in 2013 on a Kawasaki Ninja 300 parallel twin unit.
Sources: en.wikipedia.org
== Class C peptidomimetics == These structural mimetics include molecules that are highly modified when compared to their parent peptide sequence. Usually, a small-molecular scaffold is applied to project groups in analogy to the bioactive conformation of a peptide.
=== Cancer research === There is research investigating whether high dose intravenous vitamin C administration as a co-treatment will suppress cancer stem cells, which are responsible for tumor recurrence, metastasis and chemoresistance.
=50–500 mg/kg. In rats, the dose is 3300 mg/kg; in mice, 3400 mg/kg; and in cats, 800 mg/kg. Survival after doses of 8 to 9 g has been reported. Overdose effects are abdominal pain, ataxia, atrial fibrillation, bradycardia, coma, dizziness, lethargy, nausea, skin rash, tremor, vomiting, and vertigo.
CamelBak thermal sport bottle. 45 North uses aerogel to keep hands warm in its Sturmfist 5 cycling gloves. Thickening agents in paints and cosmetics. Warheads: Fogbank, a material of secret composition used in U.S. thermonuclear warheads, may be an aerogel. Waste disposal Water purification: Chalcogels can absorb metal pollutants such as mercury, lead, and cadmium. Aerogels can also absorb oil, for example to respond to oil spills. Aerogels can disinfect water. Photothermal aerogels can purify water by accelerating evaporation.
=== FDA Warning === On February 12, 2007, after an advisory committee discussion and vote in December 2006, the FDA announced a revision to the labeling of Ketek. The changes included the removal of two of the three previously approved indications: acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis. The agency determined that the balance of benefits and risks no longer supported approval of the drug for these indications. Ketek remained on the market for the treatment of community acquired bacterial pneumonia of mild to moderate severity (acquired outside of hospitals or long-term care facilities). In addition, the FDA worked with the manufacturer to update the product labeling with a "black box warning," their strongest form of warning. Ketek's warning states that it should not be used in patients with myasthenia gravis, a disease that causes muscle weakness. Following this decision, Sanofi-Aventis withdrew the drug from active sales in the United States.
Sources: en.wikipedia.org
Runs of homozygosity (ROH) are contiguous lengths of homozygous genotypes that are present in an individual due to parents transmitting identical haplotypes to their offspring. The potential of predicting or estimating individual autozygosity for a subpopulation is the proportion of the autosomal genome above a specified length, termed Froh. A research study in UK Biobank, All of Us and Million Veteran Program found that FROH declined over time in the US cohorts.
=== Loss of solubility === When proteins are folded, they fold so as to keep their hydrophobic parts on the inside (away from water) and their hydrophilic parts on the outside (contacting the water). This makes them soluble enough not to precipitate. However, when denatured the surface of the protein is partly hydrophobic and partly hydrophilic (as it no longer has an "inside" in which to hide the hydrophobic parts), causing it to become insoluble in water. The hydrophobic parts of the denatured proteins stick together, forming a network (gel): this is called coagulation. The coagulation of denatured proteins is the reason eggs solidify when cooked. When acid is added to milk, the protein casein denatures and coagulates (with fat and water inclusions from the milk) into curds, the first step in making cheese; although milk can also be made to curdle (i.e. casein to coagulate) by other methods, for example the addition of enzymes like chymosin.
The Young's modulus of a single protein can be found through molecular dynamics simulation. Using either atomistic force-fields, such as CHARMM or GROMOS, or coarse-grained forcefields like Martini, a single protein molecule can be stretched by a uniaxial force while the resulting extension is recorded in order to calculate the strain. Experimentally, methods such as atomic force microscopy can be used to obtain similar data. The internal dynamics of proteins involve subtle elastic and plastic deformations induced by viscoelastic forces, which can be probed by nano-rheology techniques. At the macroscopic level, the Young's modulus of cross-linked protein networks can be obtained through more traditional mechanical testing. Experimentally observed values for a few proteins can be seen below.
==== Active metabolites ==== A few of the metabolites of oxycodone have also been found to be active as MOR agonists, some of which notably have much higher affinity for (as well as higher efficacy at) the MOR in comparison. Oxymorphone possesses 3- to 5-fold higher affinity for the MOR than does oxycodone, while noroxycodone and noroxymorphone possess one-third of and 3-fold higher affinity for the MOR, respectively, and MOR activation is 5- to 10-fold less with noroxycodone but 2-fold higher with noroxymorphone relative to oxycodone. Noroxycodone, noroxymorphone, and oxymorphone also have longer biological half-lives than oxycodone.
== History == The US Food and Drug Administration (FDA) approved eptinezumab based primarily on evidence from two clinical trials (Trial 1/NCT02559895 and Trial 2/NCT02974153) of 1741 participants with chronic or episodic migraine headaches. Trials were conducted at 212 sites in United States, Georgia, Russia, Ukraine and the European Union. The benefit and side effects of eptinezumab were evaluated in two clinical trials of adults aged 18 through 71 years of age with a history of migraine headaches. The trials had similar designs. Trial 1 enrolled participants with a history of episodic migraine headaches and Trial 2 enrolled participants with chronic migraine headaches. Participants were assigned to receive one of two doses of eptinezumab or placebo injections every three months for a total of twelve months in Trial 1, and for a total of 6 months in Trial 2. Neither the participants nor the health care providers knew which treatment was being given until the trial was completed. The benefit of eptinezumab in comparison to placebo was assessed based on the change in the number of migraine days per month during the first three-month treatment period.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.